跳至主要内容
临床试验/NL-OMON29214
NL-OMON29214尚未招募不适用

Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation (a phase I study).

Radboud University Nijmegen Medical Centre0 个研究点目标入组 0 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients positive for HLA-A2 and/or HLA-B7.
  • - Patients positive for HA-1, LRH-1 and/or ARHGDIB transplanted with the corresponding MiHA-negative donor.

排除标准

  • - Life expectancy < 3 months.
  • - Severe neurological or psychiatric disease.

研究者

发起方
Radboud University Nijmegen Medical Centre

相似试验

已完成
不适用
Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation (a phase I study)blood cell cancerhematological malignancies10027656
NL-OMON40014niversitair Medisch Centrum Sint Radboud10
进行中(未招募)
1 期
Dendritic cells vaccination after allogeneic stem cell transplantatioPatients with aggressive hematological malignancies treated with allogeneic stem cell transplantation
EUCTR2012-002879-34-NLRadboud University Nijmegen Medical Centre
已完成
不适用
Vaccination with human minor H antigen (HA-1) peptide after allogeneic stem cell transplantatio
ISRCTN80896844eiden University Medical Centre (LUMC) (Netherlands)24
已完成
1 期
Predetermined Minor Histocompatibility Antigen-based Therapeutic or Prophylactic Peptide Vaccinations for Patients with Recurred Malignancies or Patients with High-Risk Malignancies Follwoing Allogeneic Hematopoietic Cell Transplantation.(1) Therapeutic vaccine: Any hematological malignancies recurred after allogineic hematopoietic transplanation as follows (RAEB, CMML, AML, ALL, CML, Multiple Myeloma, NHL). (2) Prophylactic vaccine: Hematological malignancies with high risk of relapse after allogineic hematopoietic transplanation as follows (RAEB, CMML, AML in &gt=3CR/non-CR or any AML with M0/M6/M7 FAB type, ALL in &gt=2CR/non-CR, CML in &gt=2CP or &gt=AP, Multiple Myeloma in PD, NHL in non-CR).
JPRN-UMIN000000872Aichi Cancer Center Research Institute12
进行中(未招募)
不适用
Donor Dendritische Cellen vaccinatie bij hematologische maligne aandoeninge
EUCTR2012-002435-28-NLniversity Medical Center Utrecht